These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections. Bregenholt S; Jensen A; Lantto J; Hyldig S; Haurum JS Curr Pharm Des; 2006; 12(16):2007-15. PubMed ID: 16787244 [TBL] [Abstract][Full Text] [Related]
4. The future of antibody therapy. Buelow R; van Schooten W Ernst Schering Found Symp Proc; 2006; (4):83-106. PubMed ID: 17824183 [TBL] [Abstract][Full Text] [Related]
5. Benefits of using heterologous polyclonal antibodies and potential applications to new and undertreated infectious pathogens. Dixit R; Herz J; Dalton R; Booy R Vaccine; 2016 Feb; 34(9):1152-61. PubMed ID: 26802604 [TBL] [Abstract][Full Text] [Related]
6. Return to the past: the case for antibody-based therapies in infectious diseases. Casadevall A; Scharff MD Clin Infect Dis; 1995 Jul; 21(1):150-61. PubMed ID: 7578724 [TBL] [Abstract][Full Text] [Related]
7. Therapeutic Antibodies for Biodefense. Avril A Adv Exp Med Biol; 2017; 1053():173-205. PubMed ID: 29549640 [TBL] [Abstract][Full Text] [Related]
8. Development of recombinant human polyclonal antibodies for the treatment of complex human diseases. Tolstrup AB; Frandsen TP; Bregenholt S Expert Opin Biol Ther; 2006 Sep; 6(9):905-12. PubMed ID: 16918257 [TBL] [Abstract][Full Text] [Related]
9. Application of camelid heavy-chain variable domains (VHHs) in prevention and treatment of bacterial and viral infections. Wilken L; McPherson A Int Rev Immunol; 2018 Jan; 37(1):69-76. PubMed ID: 29182399 [TBL] [Abstract][Full Text] [Related]
10. Investigation of a panel of monoclonal antibodies and polyclonal sera against anthrax toxins resulted in identification of an anti-lethal factor antibody with disease-enhancing characteristics. Kulshreshtha P; Tiwari A; Priyanka ; Joon S; Sinha S; Bhatnagar R Mol Immunol; 2015 Dec; 68(2 Pt A):185-93. PubMed ID: 26364143 [TBL] [Abstract][Full Text] [Related]
11. Antibodies for the prevention and treatment of viral diseases. Sawyer LA Antiviral Res; 2000 Aug; 47(2):57-77. PubMed ID: 10996394 [TBL] [Abstract][Full Text] [Related]
12. Passive antibody administration (immediate immunity) as a specific defense against biological weapons. Casadevall A Emerg Infect Dis; 2002 Aug; 8(8):833-41. PubMed ID: 12141970 [TBL] [Abstract][Full Text] [Related]
13. Recombinant polyclonal antibodies: the next generation of antibody therapeutics? Haurum JS Drug Discov Today; 2006 Jul; 11(13-14):655-60. PubMed ID: 16793535 [TBL] [Abstract][Full Text] [Related]
14. Antibody Preparations from Human Transchromosomic Cows Exhibit Prophylactic and Therapeutic Efficacy against Venezuelan Equine Encephalitis Virus. Gardner CL; Sun C; Luke T; Raviprakash K; Wu H; Jiao JA; Sullivan E; Reed DS; Ryman KD; Klimstra WB J Virol; 2017 Jul; 91(14):. PubMed ID: 28468884 [TBL] [Abstract][Full Text] [Related]
15. [From the ancient serotherapy to naked antibodies: a century of successful targeted therapies]. Watier H Med Sci (Paris); 2009 Dec; 25(12):999-1009. PubMed ID: 20035670 [TBL] [Abstract][Full Text] [Related]
16. Enhanced protection against pneumococcal infection elicited by immunization with the combination of PspA, PspC, and ClpP. Cao J; Chen D; Xu W; Chen T; Xu S; Luo J; Zhao Q; Liu B; Wang D; Zhang X; Shan Y; Yin Y Vaccine; 2007 Jun; 25(27):4996-5005. PubMed ID: 17524530 [TBL] [Abstract][Full Text] [Related]
17. [Development of antituberculous drugs: current status and future prospects]. Tomioka H; Namba K Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921 [TBL] [Abstract][Full Text] [Related]